Reviewer: Deepali Jain, M.D. (see Reviewers page)
Revised: 12 January 2013, last major update September 2012
Copyright: (c) 2003-2013, PathologyOutlines.com, Inc.
● Refers to growth pattern called lepidic, which arises from and spreads along alveolar walls without invasion
● Similar to jagziekte, a disease of South African sheep, but jagziekte DNA not identified in human tumors
● IASLC/ATS/ERS classification (Mod Pathol 2011;24:653): BAC no longer a valid diagnosis
● WHO definition: adenocarcinoma with bronchioloalveolar pattern and no evidence of stromal, vascular, or pleural invasion, based on complete resection specimen
Bronchioloalveolar carcinoma: how to classify tumors now
1. <=3cm, NO stromal, lymphatic, vascular or pleural invasion, no necrosis, no growth patterns other than lepidic:
● Adenocarcinoma in situ, either serous or mucinous
2. <=3cm, with <=5mm area of stromal invasion or growth pattern(s) other than lepidic:
● Minimally Invasive Adenocarcinoma (MIA)
3. >3cm OR lymphatic, vascular or pleural invasion OR necrosis OR >5mm area of stromal invasion OR growth pattern(s) other than lepidic:
● Serous: invasive adenocarcinoma, lepidic predominant or
● Mucinous: invasive mucinous adenocarcinoma
● Invasion defined as histological subtypes other than lepidic or presence of a myofibroblastic stroma associated invasive tumor
● For tumors with multiple foci, measure largest dimension on a single slide; do NOT sum invasive foci on all slides
Mucinous: H&E, TTF1, CK7, CK20
Nonmucinous (H&E, TTF1, CK7, CK20)
End of Lung tumor > Other carcinoma > Bronchioloalveolar carcinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).